SG3 Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SG3 Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,900	Closed	-$3.38M	–	311
2022 Q3	$3.38M	Buy	+4,900	New	+$3.08M	0.45%	47
2021 Q2	–	Sell	-20,000	Closed	-$9.46M	–	1273
2021 Q1	$9.46M	Buy	20,000 +17,500	+700%	+$8.52M	0.24%	93
2020 Q4	$1.21M	Buy	+2,500	New	+$1.35M	0.02%	509
2018 Q1	–	Sell	-1,500	Closed	-$564K	–	125
2017 Q4	$564K	Hold	1,500	–	–	0.18%	72
2017 Q3	$671K	Hold	1,500	–	–	0.15%	95
2017 Q2	$737K	Buy	+1,500	New	+$656K	0.18%	118

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SG3 Management's REGN Position: Q1 2022 in Review

SG3 Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 200 shares — an estimated $126K sold.

SG3 Management first reported a position in REGN in Q2 2021 and held it in 3 quarters. The position peaked at $303K in Q3 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

SG3 Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 200 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $126K.
SG3 Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 3 quarters.
SG3 Management's Regeneron Pharmaceuticals position peaked at $303K in Q3 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.